PASSUR Aerospace Reports an Increase in Net Income of 9% to $2.9 Million for Fiscal Year 2012

STAMFORD, Conn., Jan. 30, 2013 /PRNewswire/ --PASSUR Aerospace, Inc (PSSR), a business intelligence software and solutions company, announced that net income increased 9% to $2,861,000 or $.36 per diluted share for the fiscal year ended October 31, 2012, compared to $2,634,000 or $.39 per diluted share in the fiscal year ended October 31, 2011. Included in net income for fiscal years 2012 and 2011 was an income tax benefit of $1,776,000, and $1,572,000, respectively.

Total Company revenue decreased 8% to $12,507,000 for the fiscal year ended October 31, 2012, compared to $13,609,000 in the fiscal year ended October 31, 2011, despite all-time record revenue of slightly over $10 million from the Company's North American airline, airport, and business aviation sector. Fiscal year 2012 revenue from this sector was about 7% above fiscal year 2011's level of approximately $9,500,000. For the first time, PASSUR customers include all eight of the top eight North American airlines.

Revenue from PASSUR's international, professional services, and government sector dropped approximately 43%, to about $2.4 million, compared to approximately $4.3 million in fiscal year 2011, as a result of the completion of a government contract and of a professional service engagement.

Operating profit for fiscal year 2012 decreased approximately 30% to $1,378,000, compared to $1,974,000 in fiscal year 2011. Income before taxes increased $23,000, or 2%, to $1,085,000 in fiscal year 2012, compared to $1,062,000 in the prior year.

PASSUR's major achievements and developments during fiscal year 2012 are summarized below. The Company:

"We continue to experience growth in our core commercial markets," said Jim Barry, PASSUR Aerospace's President & CEO. "We are proud that revenue from our North American airline, airport, and business aviation sector reached a record level last year. We are also particularly pleased to announce that, for the first time, all eight of North America's top airlines are contracting with PASSUR. This is a major achievement for the company and testimony to the value of our new PASSUR Integrated Traffic Management platform and, we believe, its positive impact on our customers' overall system reliability as well as cash flow. Finally, our continued investment in collaborative industrial social networks introduces the PASSUR platform to a worldwide community of aviation professionals the next generation of PASSUR customers."

"We believe our customers can, using PASSUR's unique product suite, address costs and problems previously thought unsolvable, by leveraging Big Data, collaborative platforms, industrial social networks, and smart decision support technology," said G.S. Beckwith Gilbert, PASSUR Aerospace Chairman of the Board.

About PASSUR Aerospace, Inc. PASSUR Aerospace, Inc. is a business intelligence company that provides predictive analytics built on proprietary algorithms and the concurrent integration and simultaneous mining of multiple databases. We believe PASSUR is the industry standard in business intelligence dashboards and predictive analytics for aviation organizations. PASSUR serves dozens of airlines (including the top eight North American airlines), approximately 60 airport customers (including 22 of the top 30 North American airports), and approximately 200 corporate aviation customers, as well as the U.S. government. PASSUR's system provides coast-to-coast coverage and is driven by proprietary, patented, business intelligence software, which is powered by a unique North American network of 155 passive radars, company owned. Supplementary, detailed coverage is also provided at 98 of the top 100 North American airports. Other PASSURs are located in Europe and Asia. Flight tracks are updated between 1 and 4.6 seconds, thereby making available a system, which is user-friendly and useful for decision-making. Visit PASSUR Aerospace's website at http://www.passur.com for updated products, solutions, and news.

Forward-Looking Statements The information provided in this press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's future plans, objectives, and expected performance. The words "believe," "may," "will," "could," "should," "would," "anticipate," "estimate," "expect," "project," "intend," "objective," "seek," "strive," "might," "likely result," "build," "grow," "plan," "goal," "expand," "position," or similar words, or the negatives of these words, or similar terminology, identify forward-looking statements. These statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties, and a number of factors could cause the Company's actual results to differ materially from those expressed in the forward-looking statements referred to above. These factors include, without limitation: the ability of the Company to sell data subscriptions from its PASSUR Proprietary Surveillance Network and to make new sales of its PASSUR and other product lines (due to potential competitive pressure from other companies or other products); the current uncertainty in the aviation industry due to terrorist events, the continued war on terrorism, changes in fuel costs, airline bankruptcies and consolidations; economic conditions; future changes in governmental regulation and the impact that such changes in regulation will have on the Company's business; the Company's ability to attract and maintain the personnel necessary to sell, manufacture, and service its products; the Company's ability to adequately protect its intellectual property; the Company's ability to secure future financing; the Company's ability to maintain the continued support of its significant shareholder and the risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which relate only to events as of the date on which the statements are made and which reflect management's analysis, judgments, belief, or expectation only as of such date. The Company undertakes no obligation to publicly update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. Readers are advised, however, to consult any further disclosures we make on related subjects in our Forms 10-K, 10-Q, and 8-K.

Read the original:

PASSUR Aerospace Reports an Increase in Net Income of 9% to $2.9 Million for Fiscal Year 2012

B/E Aerospace Reports Fourth Quarter and Full Year 2012 Financial Results; Fourth Quarter 2012 EPS Up 30%; Full Year …

WELLINGTON, Fla.--(BUSINESS WIRE)--

B/E Aerospace, Inc. (BEAV), the worlds leading manufacturer of aircraft cabin interior products and the worlds leading distributor of aerospace fasteners and consumables, today announced fourth quarter and full year 2012 financial results.

FOURTH QUARTER 2012 HIGHLIGHTS VERSUS FOURTH QUARTER PRIOR YEAR

FULL YEAR 2012 HIGHLIGHTS VERSUS FULL YEAR 2011

2013 FINANCIAL GUIDANCE

FOURTH QUARTER CONSOLIDATED RESULTS

Fourth quarter 2012 revenues of $803.2 million increased $148.5 million, or 22.7 percent, as compared with the prior year period.

Operating earnings were $138.1 million, an increase of 26.6 percent, and operating margin of 17.2 percent increased 50 basis points. The growth in operating earnings and the improvement in operating margin occurred primarily as a result of operating leverage at the higher sales volume and ongoing operational efficiency initiatives. Operating earnings and operating margin, adjusted to exclude acquisition, integration and transition (AIT) costs, were $142.2 million and 17.7 percent.

Net earnings and earnings per diluted share were $75.2 million and $0.73 per share, increases of 31.2 percent and 30.4 percent, respectively.

Commenting on the Companys fourth quarter and full year 2012 performance, Amin J. Khoury, Chairman and Chief Executive Officer of B/E Aerospace said, I am pleased to report, our 2012 results which were the best in the Companys history. 2012 revenues, operating earnings, operating margin, bookings and backlog were all records, and net earnings and EPS, adjusted to exclude debt prepayment costs, were also records. Our revenue growth continues to be driven primarily by the robust new aircraft delivery cycle. Approximately 61 percent of fourth quarter and full year 2012 revenues was driven by demand for products for new-buy aircraft reflecting both robust new aircraft deliveries and weaker aftermarket demand.

Continue reading here:

B/E Aerospace Reports Fourth Quarter and Full Year 2012 Financial Results; Fourth Quarter 2012 EPS Up 30%; Full Year ...

Sikorsky Aerospace Services Provides In-Country Depot Level Repairs to Colombian Army BLACK HAWK Fleet

SHELTON, Conn., Jan. 30, 2013 /PRNewswire/ --Sikorsky Aerospace Services (SAS) today announced plans to structurally repair seven damaged UH-60L BLACK HAWK helicopters for the Colombian Army (COLAR) at its base depot in Tolemaida, Colombia. To ensure sustained support for operations as mandated by the Colombian Army, the Colombian Army Aviation (part of the Army's Combined Arms Team) has continued to expand its in-country BLACK HAWK maintenance services tripling the size of the Sikorsky Depot Team. Sikorsky Aerospace Services (SAS) is the aftermarket business of Sikorsky Aircraft Corp., a subsidiary of United Technologies Corp. (UTX).

(Logo: http://photos.prnewswire.com/prnh/20060403/SIKORSKYLOGO )

"Colombia has been our valued customer for over thirty years. Our ability to support the operational readiness of the Colombian Armed Services is paramount in their efforts to ensure national order and security," said Frank DiPasquale, SAS Vice-President of Sales & Strategic Relationships. "The capacity to perform these repairs in-country will represent significant savings to our customer and underscores our ability to be a full life-cycle service provider. The success of this program provides economical options for Sikorsky BLACK HAWK operators worldwide."

Colombia operates the world's fourth-largest BLACK HAWK fleet. The technical and tactical characteristics of the UH-60L fleet provide the mobility and penetration required by the Colombian Army to execute a variety of dynamic missions. To provide the requisite support to COLAR units, the Air Assault Aviation Division of the National Army requires optimum fleet readiness and airworthiness. The UH-60L aircraft support air assault, reconnaissance, supply and other missions.

Sikorsky Aircraft Corp., based in Stratford, Conn., is a world leader in helicopter design, manufacture and service. Its Sikorsky Aerospace Services business designs and applies advanced logistics and supply chain solutions for commercial rotary, military rotary and fixed wing operators. United Technologies Corp., based in Hartford, Conn., provides a broad range of high technology products and support services to the aerospace and building systems industries worldwide.

See the article here:

Sikorsky Aerospace Services Provides In-Country Depot Level Repairs to Colombian Army BLACK HAWK Fleet

ReNeuron Group edges further in stem cell therapy research for stroke patients

LONDON (ShareCast) - ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday.

The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.

ReNeuron is now set to proceed with dosing the last three patients after getting clearance from the Data Safety Monitoring Board which reviewed the study.

The first of the three patients was treated with ReN001 and discharged from hospital. The remaining two are scheduled to be treated this March.

Last year, interim data from the first five patients treated in the study were presented by the Glasgow clinical team. Sustained reductions in neurological impairment and spasticity were observed in all patients compared with their stable pre-treatment baseline performance.

Further and longer term data from the study are expected to be presented in scientific conference later this year.

The company has submitted an application to the UK regulatory authority to commence a multi-site phase two clinical trial to examine the efficacy of ReN001 in patients disabled by an ischaemic stroke. Preparations are underway to begin the trial mid-year.

RD

Read more:
ReNeuron Group edges further in stem cell therapy research for stroke patients

Pfizer 4th-Quarter Profit Surges Amid Gain From Nutrition Unit Sale

Pfizer Inc. (PFE) reported a surge in fourth-quarter profit on a gain from the sale of its nutrition unit, while generic competition for cholesterol-lowering drug Lipitor contributed to a 7% sales decline.

The drug maker's quarterly results exceeded Wall Street expectations, and Pfizer issued an initial 2013 financial forecast that roughly bracketed analysts' current estimates.

Pfizer shares rose 66 cents, or 2.4%, to $27.50, in recent trading and earlier touched a multi-year high. The stock is up 28% over the past 12 months.

Pfizer is trying to bounce back from the late 2011 loss of U.S. exclusivity for its cholesterol-lowering pill Lipitor, which triggered generic competition that eroded sales of what was once the best-selling prescription drug in the world.

The company has tried to overcome the Lipitor loss by expanding sales of other drugs that remain patent-protected, such as the pain drug Lyrica, as well as introducing new products with sizeable market potential.

These include Xeljanz, a new treatment for rheumatoid arthritis that was approved by the U.S. Food and Drug Administration in November, and Eliquis, an anticlotting drug co-developed with Bristol-Myers Squibb Co. (BMY) that was cleared by FDA in late December. Analysts expect the drugs to eventually generate billions of dollars in annual sales.

At the same time, Pfizer has taken steps perceived to be "shareholder friendly" over the past two years, including share buybacks, spending cuts, as well as the divestitures of certain non-pharmaceutical assets. Pfizer sold its nutrition business to Nestle for $11.85 billion cash in November, and it will soon stage an initial public offering of up to a 19.8% stake in its animal health unit, Zoetis, with the potential to shed its remaining stake at a later date.

The Zoetis IPO is expected Friday in what would be the largest IPO from a U.S. company since Facebook Inc.'s (FB) last May.

During a conference call Tuesday morning, Pfizer Chief Executive Ian Read reiterated comments suggesting the company could conduct further splits. He said Pfizer was evolving toward two business models, each with separate management: one with patented, innovative drugs and the other with off-patent drugs. He said Pfizer would eventually have to decide whether shareholders want to invest in these as two distinct companies, but that such a decision wasn't a near-term priority.

Mr. Read also said he expected the company to continue to pursue "bolt-on" acquisitions and other business-development deals to supplement the company's internal research-and-development efforts. He didn't, however, set a maximum value for potential deals, and said the company wouldn't rule out any deal that adds to shareholder value.

Read the original post:
Pfizer 4th-Quarter Profit Surges Amid Gain From Nutrition Unit Sale

The Makers of Hydroxycut Focus on Important Data on Nutrition Labels

NEW YORK, NY--(Marketwire - Jan 29, 2013) - The nutrition labels on foods are important for dieters who are planning their meals and making healthy choices. For this reason, the makers of Hydroxycut have shared some tips regarding which details provided on nutrition labels should be of particular interest to dieters. These tips are in response to an article, which breaks down what a registered dietitian looks for when choosing her meals.

The article reveals that paying special attention to serving size, grams of saturated and trans fats, and the ingredients are crucial. Serving size is important because portion control is one key to weight loss and many foods measure their nutritional content based on a serving size that is much smaller or even larger than the average person would consume. Saturated and trans fats are substances that should be limited, so instead of looking at how many grams of total fat a food has, people should choose foods that have low saturated and trans fats (as other fats in moderation can be important to a balanced diet). Additionally, by looking at the ingredients, people are able to emphasize whole ingredients in their diet. As such, they can cut down on other unwanted substances. The article explains that people should not always put special emphasis on grams of fat, as discussed, or on daily percentage value.

The makers of Hydroxycut encourage dieters to take the advice set forth in the article, because it provides a great deal of insight into choosing the right foods. In a recent press statement, the makers of Hydroxycut announce: "We are always looking for new ways to help individuals achieve their weight loss goals. In this article, we discover great information regarding how to read a nutrition label so that it can benefit one's dietary efforts. By looking at the right details, people can create a well-rounded, healthy meal plan that fits their individual needs."

ABOUT: Hydroxycut is the number one, best-selling weight-loss supplement brand in America. The key weight-loss ingredients in Pro Clinical Hydroxycut are lady's mantle extract, wild olive extract, komijn extract, and wild mint extract. These ingredients have demonstrated the ability to help reduce BMI and encourage weight loss for participants involved in two clinical studies. In the first study, the average weight loss with these key ingredients was 20.94 pounds over a 12-week period. In the second study, the average weight loss was 16.50 pounds over an 8-week period.All groups involved in these studies followed a reduced-calorie diet.

Hydroxycut is available in several formats, including Pro Clinical Hydroxycut Caffeine Free, Hydroxycut Herbal, and more.

For more information, visit http://www.Hydroxycut.com.

Original post:
The Makers of Hydroxycut Focus on Important Data on Nutrition Labels

Nutrition Wellness Center of Sarasota Considers the Impact of Toxins on Newborns

SARASOTA, FL--(Marketwire - Jan 29, 2013) - Environmental toxins are present in nearly everything that people come in contact with, from the air they breathe to the food they eat and the products they use. As such, these toxins have the potential to cause a wide range of illnesses and other medical conditions in the people who are most vulnerable to them. A recent article published by Philly.com reveals a surprising demographic that can suffer tremendously from toxic exposure: newborn babies. The professionals at Nutrition Wellness Center Sarasota explain how children are vulnerable to these toxins before they even enter the world.

According to the article, 10 newborns tested positive for over 200 different synthetic chemicals. Ken Cook, who gave a reportedly passionate speech to a Senate subcommittee on the matter and is the president of a national advocacy group called the Environmental Working Group, comments regarding these children: "Their chemical exposures did not come from the air they breathed, the water they drank, or the food they ate." He continued by saying, "Babies are coming into this world pre-polluted with toxic chemicals."

The odds of this happening may seem slim at first glance, as infants enjoy the protection of the womb before entering the world; however, the professionals at Nutrition Wellness Center understand that the womb is not foolproof and a long list of toxic substances can make its way to a child before it is born.

"Unfortunately, many toxins are passed through the umbilical cord from a mother to her unborn child that have the potential to impact a long list of the body's systems, including the immune system, the endocrine system, and, most importantly, the brain and the rest of the nervous system," comments Dr. James Martin of Nutrition Wellness Center of Sarasota. "Once a child is born they drink more, eat more, and breathe faster than adults by weight, which results in them experiencing heavier exposure to certain toxins. Babies cannot store toxins in their fat cells or excrete them as adults can, and the blood-brain barrier is not fully developed until they are six months of age. As such, infants are much more vulnerable to the ill effects of toxins because their defense systems are not fully developed. The exposure to too many toxins can mean that newborns suffer from developmental delays in virtually all areas of their total growth, as well as hormonal issues."

Dr. Martin and his team encourage individuals to learn more about toxicity and how they can address the specific and non-specific illnesses that such exposure can cause. Screenings for toxic exposure, Dr. Martin asserts, are a great way for individuals to determine if they have come into contact with dangerous substances that could be causing medical concerns.

ABOUT:

Nutrition Wellness Center Sarasota is a healthcare center that offers several services to its clients, including weight loss and detoxification solutions. Through the leadership of Dr. James Martin, Nutrition Wellness Center of Sarasota individualizes the procedures it offers to clients who reside across the United States. The goal of Nutrition Wellness Center of Sarasota is to provide tailored, effective weight loss and detoxification solutions that address the root causes of issues that clients face, such as toxicity.

The rest is here:
Nutrition Wellness Center of Sarasota Considers the Impact of Toxins on Newborns

Photo Release — Complete Nutrition Teams Up With Former NFL Super Bowl Champ Mike Alstott

OMAHA, Neb., Jan. 30, 2013 (GLOBE NEWSWIRE) -- Complete Nutrition, the fast-growing nutritional supplement retailer known for its consultative approach to health and fitness, announces a partnership with Tampa Bay Buccaneers legend Mike Alstott, marking the company's first national deal with a professional athlete. Alstott will serve as a spokesman and appear in marketing campaigns to promote Complete Nutrition's Mancore line of testosterone-boosting and weight-loss supplements geared toward active men ages 30 to 55.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16912

Throughout a 12-year NFL career, six-time Pro Bowl fullback and 2003 Super Bowl champion Mike "A-Train" Alstott was known for his grit, power and meticulous work ethic that allowed him to run through defenders to reach the end zone. Even in retirement, Alstott continues to train hard and eat healthy, making him an ideal representative of Complete Nutrition's Mancore brand.

Alstott, 39, personally uses the Mancore 3-Pack testosterone-boosting, growth-hormone-enhancing and fat-burning program and reported losing 15 lbs. in five weeks, gaining muscle, sleeping better and having an increased libido. The Bucs' all-time leader in touchdowns says Mancore helps him stay physically fit despite living a full schedule, which involves raising a family, serving as head coach for the Northside Christian high school football team in St. Petersburg, Fla., and being involved in other business ventures. In addition, Alstott champions the all-around wellness of children and families facing life-altering obstacles through the Mike Alstott Family Foundation.

"Men my age don't realize that our testosterone levels are decreasing, but it's a reality that makes staying fit more difficult," said Alstott. "Guys often have a hard time getting over that initial hump to where they truly see results. I've tried a lot of other supplements and had trouble getting past my plateau until Mancore. Since using Mancore, I've trimmed down immensely and my muscles are more defined. People have even told me I look like I'm still in playing shape."

Mancore 3-Pack, the most comprehensive product in the Mancore line, helps men increase muscle mass, strength and energy, as well as burn fat and improve body composition. The exclusive program contains three complementary products: Total Fat Burn, Testosterone Replenish and HGH Night Spray. These are designed to work in tandem, maximizing the effectiveness of each individual product and helping users look lean and fit.

Total Fat Burn, formulated with naturally occurring synephrine HCl, green coffee bean extract and green tea extract, helps improve body composition, boosts metabolism and increases energy. Testosterone Replenish enhances libido and stamina and replenishes youthful hormones with a blend of testosterone support ingredients, including DHEA. The convenient HGH Night Spray, taken before bedtime, increases growth hormone levels by up to 157 percent and improves sleep quality with its key ingredient, melatonin.

"We are honored to have such a storied NFL role model as part of the Complete Nutrition brand," said Amy Bailey, VP of Marketing for Complete Nutrition. "Mike Alstott is a guy the Mancore demographic can relate to and he's a great inspiration for men across the country to get in shape."

Kicking off the partnership, the official Mancore website, MancoreResults.com, features exclusive content of Alstott such as pictures and quotes, and tips from the football legend on diet, nutrition and exercise. Customers can also visit the site to read about the science behind the products and watch a video on Mancore. Other marketing elements of the partnership include a radio campaign with Alstott endorsing the Mancore line and in-store displays featuring the former NFL fullback.

The entire Mancore line, including the Mancore 3-Pack, individual products and the Mancore Muscle Preserve are available at all Complete Nutrition stores. Visit CompleteNutrition.com to find the nearest store and more information.

Read more here:
Photo Release -- Complete Nutrition Teams Up With Former NFL Super Bowl Champ Mike Alstott

Complete Nutrition Teams Up With Former NFL Super Bowl Champ Mike Alstott

OMAHA, NE--(Marketwire - Jan 30, 2013) - Complete Nutrition, the fast-growing nutritional supplement retailer known for its consultative approach to health and fitness, announces a partnership with Tampa Bay Buccaneers legend Mike Alstott, marking the company's first national deal with a professional athlete. Alstott will serve as a spokesman and appear in marketing campaigns to promote Complete Nutrition's Mancore line of testosterone-boosting and weight-loss supplements geared toward active men ages 30 to 55.

Throughout a 12-year NFL career, six-time Pro Bowl fullback and 2003 Super Bowl champion Mike "A-Train" Alstott was known for his grit, power and meticulous work ethic that allowed him to run through defenders to reach the end zone. Even in retirement, Alstott continues to train hard and eat healthy, making him an ideal representative of Complete Nutrition's Mancore brand.

Alstott, 39, personally uses the Mancore 3-Pack testosterone-boosting, growth-hormone-enhancing and fat-burning program and reported losing 15 lbs. in five weeks, gaining muscle, sleeping better and having an increased libido. The Bucs' all-time leader in touchdowns says Mancore helps him stay physically fit despite living a full schedule, which involves raising a family, serving as head coach for the Northside Christian high school football team in St. Petersburg, Fla., and being involved in other business ventures. In addition, Alstott champions the all-around wellness of children and families facing life-altering obstacles through the Mike Alstott Family Foundation.

"Men my age don't realize that our testosterone levels are decreasing, but it's a reality that makes staying fit more difficult," said Alstott. "Guys often have a hard time getting over that initial hump to where they truly see results. I've tried a lot of other supplements and had trouble getting past my plateau until Mancore. Since using Mancore, I've trimmed down immensely and my muscles are more defined. People have even told me I look like I'm still in playing shape."

Mancore 3-Pack, the most comprehensive product in the Mancore line, helps men increase muscle mass, strength and energy, as well as burn fat and improve body composition. The exclusive program contains three complementary products: Total Fat Burn, Testosterone Replenish and HGH Night Spray. These are designed to work in tandem, maximizing the effectiveness of each individual product and helping users look lean and fit.

Total Fat Burn, formulated with naturally occurring synephrine HCl, green coffee bean extract and green tea extract, helps improve body composition, boosts metabolism and increases energy. Testosterone Replenish enhances libido and stamina and replenishes youthful hormones with a blend of testosterone support ingredients, including DHEA. The convenient HGH Night Spray, taken before bedtime, increases growth hormone levels by up to 157 percent and improves sleep quality with its key ingredient, melatonin.

"We are honored to have such a storied NFL role model as part of the Complete Nutrition brand," said Amy Bailey, VP of Marketing for Complete Nutrition. "Mike Alstott is a guy the Mancore demographic can relate to and he's a great inspiration for men across the country to get in shape."

Kicking off the partnership, the official Mancore website, MancoreResults.com, features exclusive content of Alstott such as pictures and quotes, and tips from the football legend on diet, nutrition and exercise. Customers can also visit the site to read about the science behind the products and watch a video on Mancore. Other marketing elements of the partnership include a radio campaign with Alstott endorsing the Mancore line and in-store displays featuring the former NFL fullback.

The entire Mancore line, including the Mancore 3-Pack, individual products and the Mancore Muscle Preserve are available at all Complete Nutrition stores. Visit CompleteNutrition.com to find the nearest store and more information.

About Mike AlstottMike Alstott is a six-time Pro Bowl fullback who played for the Tampa Bay Buccaneers throughout his entire 12-year NFL career. Known for his rigorous training regimen and power, Alstott earned the nickname A-Train by running through opponents. Alstott is the Buccaneers' all-time leader in total touchdowns (71) and rushing touchdowns (58) and ranks second all-time on the club's rushing list with 5,088 yards. He is currently the President of the Mike Alstott Family Foundation (www.mikealstottfamilyfoundation.org), whose mission is "to assist others in uplifting the minds, hearts and spirits of families and children on their way to realizing their full potential through various events, assistance programs, and celebrations."

Go here to see the original:
Complete Nutrition Teams Up With Former NFL Super Bowl Champ Mike Alstott

“What Matters to Me and Why” – A Discussion with Professor Hung Fan – Video


"What Matters to Me and Why" - A Discussion with Professor Hung Fan
Our "What Matters to Me and Why" series of informal discussions with respected members of our faculty continues to build momentum. Our premiere conversations with University Professor Francisco J. Ayala and physics Professor Clare Yu have generated favorable reviews from students, faculty and staff. For those who attended, thank you for your participation and feedback. We #39;re heartened by your enthusiastic response. For those who could not attend, videos of the past talks can be viewed here. "What Matters to Me and Why" encourages reflection about values, beliefs and motivations in the lives of those who shape our university. We will explore personal journeys -- choices made, difficulties encountered, commitments grasped and joys revealed -- with the hope that these stories will strengthen our bonds and fortify the virtues that make UC Irvine a great institution. The series continues Jan. 16 with Hung Fan, professor of virology and molecular biology in the School of Biological Sciences, and director of the Cancer Research Institute. Professor Fan investigates retroviruses to understand how they replicate and cause cancer. His work has appeared in numerous publications, and he is a fellow of the American Association for the Advancement of Science and the American Academy of Microbiology. The series continues each month, except for December and June, throughout the academic year. Please check the website or posters on campus for future speakers. We encourage you to ...

By: UCIrvineOCW

View post:
"What Matters to Me and Why" - A Discussion with Professor Hung Fan - Video

How research is important in virology – Video


How research is important in virology
Youtube Video Assignment by: Aleena Dipede and Allison Bourne References: Breman, JG, de Quadros, CA, Dowdle, WR, Foege, WH, Henderson, DA, John, TJ, Levine, MM (2011). The role of research in viral disease eradication and elimination programs: lessons for malaria eradication. PLOS Medicine, 8(1), Retrieved from http://www.plosmedicine.org Enquist, LW (2009). Virology in the 21st century. Journal of Virology, 83(11), doi: 10.1128/JVI.00151-09 Jeang, K. (2009). The importance of individualized article-specific metrics for evaluating research productivity. Retrovirology, 6(82), doi: 10.1186/1742-4690-6-82 Miyazaki, Y., Fujita, M., Nomaguchi, M., Adachi, A. (2012). Structural biology for virus research. Frontiers in Microbiology, 3(91), 1-2. doi: 10.3389/fmicb.2012.00091 Nomaguchi , M., Adachi, A. (2010). Virology as biosystematics: towards understanding the viral infection biology. Frontiers in Microbiology, 1(2), doi: 10.3389/fmicb.2010.00002

By: Aleena D

Read more:
How research is important in virology - Video

Acer Team Unlimited AspireS7 Susan


Acer Team Unlimited AspireS7 Susan Rock star Franco_0002.wmv
Susan #39;s on a quest with her new Acer AspireS7 laptop, as 1 of 4 finalists http://www.acerteamunlimited.com.au to have her dream project win $25000 to make it HAPPEN! Support her organic gardening, learning about life cycles and microbiology 4 science dream to develop Apps for children and school gardening programs. VOTE to do your bit for the environment to grow food locally, putting carbon from the air back into the ground. Follow @susan_acer_tu and http://www.facebook.com

By: Susan McKinnon

Excerpt from:
Acer Team Unlimited AspireS7 Susan

Research and Markets: Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/x4j4d8/asiapacific_in) has announced the addition of GlobalData's new report "Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" to their offering.

Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture provides key market data on the Asia-Pacific In Vitro Diagnostics market - Australia, China, India and Japan. The report provides value (USD million) data for all the market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

Scope

- Countries covered include Australia, China, India and Japan.

- Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.

- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the market categories and countries.

- Global corporate-level profiles of key companies operating within the Asia-Pacific In Vitro Diagnostics market..

- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Sysmex Corporation, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc. and others.

Continued here:
Research and Markets: Asia-Pacific In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing ...

Research and Markets: New Zealand In Vitro Diagnostics Market Outlook to 2018 – Clinical Chemistry Genetic Testing …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cqng7x/new_zealand_in) has announced the addition of GlobalData's new report "New Zealand In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" to their offering.

Our new report, New Zealand In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture provides key market data on the New Zealand In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within market categories - Clinical Chemistry, Haematology, Immuno Chemistry, Histology And Cytology, Infectious Immunology, Microbiology Culture and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

Scope

- Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Haematology, Immuno Chemistry, Histology And Cytology, Infectious Immunology, Microbiology Culture and Genetic Testing.

- Annualized market revenues (USD million) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the market categories.

- Global corporate-level profiles of key companies operating within the New Zealand In Vitro Diagnostics market.

- Key players covered include Sysmex Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Beckman Coulter, Inc., Siemens Healthcare, Becton, Dickinson and Company and others.

Key Topics Covered:

See the rest here:
Research and Markets: New Zealand In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing ...

Global Microbiology Testing Market Analyzed in New Cutting-Edge Report by VPG Published at Marketpublishers.com

LONDON--(BUSINESS WIRE)--

The microbiology testing market is one of the most rapidly evolving segments of the IVD industry globally. Some of the major forces propelling the market include the unceasing propagation of AIDS, cloud of bioterrorism, revolutionarymolecular diagnostic technologies, and wider accessibility of immunosuppressive medications. Furthermore, recent breakthroughs in genetic engineering (GE) are creating capturing opportunities for highly sensitive, specific and cost-effective products. With all these advantages though, there are also huge challenges faced by suppliers these days.

New research study 2012 World Microbiology Market Strategic Analysis: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Country drawn up by Venture Planning Group (VPG) provides a worldwide overview of the microbiology testing market environment, dynamics, trends, structure, sizing and growth potential.

The report provides market segmentation analysis of over 90 diseases and viruses in the seven countries (France, Germany, Italy, Japan, Spain, the UK, and the US), assesses emerging technologies, and reviews current instrumentation. It also features estimates of the number of laboratories performing microbiology tests, as well as test volume and sales projections for microbiology assays by country. The research provides strategic profiles of 32 major suppliers and emerging market entrants with innovative technologies and products. Additionally, emerging opportunities for various products with significant market appeal during the next decade are examined, as well as strategic recommendations are given.

Report Details:

Title: 2012 World Microbiology Market Strategic Analysis: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Country

Published: December, 2012

Pages: 1900

Price: US$ 28,700.00

http://marketpublishers.com/report/in_vitro_diagnostics/microbiology-virology/2012-world-microbiology-market-strategic-analysis-supplier-shares-n-sales-forecasts-4-100-infectious-disease-tests-by-country.html

Read the rest here:
Global Microbiology Testing Market Analyzed in New Cutting-Edge Report by VPG Published at Marketpublishers.com